1
|
Recent Strategic Advances in CFTR Drug Discovery: An Overview. Int J Mol Sci 2020; 21:ijms21072407. [PMID: 32244346 PMCID: PMC7177952 DOI: 10.3390/ijms21072407] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Revised: 03/25/2020] [Accepted: 03/27/2020] [Indexed: 12/13/2022] Open
Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR)-rescuing drugs have already transformed cystic fibrosis (CF) from a fatal disease to a treatable chronic condition. However, new-generation drugs able to bind CFTR with higher specificity/affinity and to exert stronger therapeutic benefits and fewer side effects are still awaited. Computational methods and biosensors have become indispensable tools in the process of drug discovery for many important human pathologies. Instead, they have been used only piecemeal in CF so far, calling for their appropriate integration with well-tried CF biochemical and cell-based models to speed up the discovery of new CFTR-rescuing drugs. This review will give an overview of the available structures and computational models of CFTR and of the biosensors, biochemical and cell-based assays already used in CF-oriented studies. It will also give the reader some insights about how to integrate these tools as to improve the efficiency of the drug discovery process targeted to CFTR.
Collapse
|
2
|
Pavlovic Z, Adams JJ, Blazer LL, Gakhal AK, Jarvik N, Steinhart Z, Robitaille M, Mascall K, Pan J, Angers S, Moffat J, Sidhu SS. A synthetic anti-Frizzled antibody engineered for broadened specificity exhibits enhanced anti-tumor properties. MAbs 2018; 10:1157-1167. [PMID: 30183492 DOI: 10.1080/19420862.2018.1515565] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Secreted Wnt ligands play a major role in the development and progression of many cancers by modulating signaling through cell-surface Frizzled receptors (FZDs). In order to achieve maximal effect on Wnt signaling by targeting the cell surface, we developed a synthetic antibody targeting six of the 10 human FZDs. We first identified an anti-FZD antagonist antibody (F2) with a specificity profile matching that of OMP-18R5, a monoclonal antibody that inhibits growth of many cancers by targeting FZD7, FZD1, FZD2, FZD5 and FZD8. We then used combinatorial antibody engineering by phage display to develop a variant antibody F2.A with specificity broadened to include FZD4. We confirmed that F2.A blocked binding of Wnt ligands, but not binding of Norrin, a ligand that also activates FZD4. Importantly, F2.A proved to be much more efficacious than either OMP-18R5 or F2 in inhibiting the growth of multiple RNF43-mutant pancreatic ductal adenocarcinoma cell lines, including patient-derived cells.
Collapse
Affiliation(s)
- Zvezdan Pavlovic
- a Terrence Donnelly Centre for Cellular and Biomolecular Research , University of Toronto , Toronto , Canada
| | - Jarrett J Adams
- a Terrence Donnelly Centre for Cellular and Biomolecular Research , University of Toronto , Toronto , Canada
| | - Levi L Blazer
- a Terrence Donnelly Centre for Cellular and Biomolecular Research , University of Toronto , Toronto , Canada
| | - Amandeep K Gakhal
- a Terrence Donnelly Centre for Cellular and Biomolecular Research , University of Toronto , Toronto , Canada
| | - Nick Jarvik
- a Terrence Donnelly Centre for Cellular and Biomolecular Research , University of Toronto , Toronto , Canada
| | - Zachary Steinhart
- b Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy , University of Toronto , Toronto , Canada
| | - Mélanie Robitaille
- b Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy , University of Toronto , Toronto , Canada
| | - Keith Mascall
- b Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy , University of Toronto , Toronto , Canada
| | - James Pan
- a Terrence Donnelly Centre for Cellular and Biomolecular Research , University of Toronto , Toronto , Canada
| | - Stephane Angers
- b Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy , University of Toronto , Toronto , Canada.,c Department of Biochemistry , University of Toronto , Toronto , Canada
| | - Jason Moffat
- a Terrence Donnelly Centre for Cellular and Biomolecular Research , University of Toronto , Toronto , Canada.,d Department of Molecular Genetics , University of Toronto , Toronto , Canada.,e Canadian Institute for Advanced Research , Toronto , Canada
| | - Sachdev S Sidhu
- a Terrence Donnelly Centre for Cellular and Biomolecular Research , University of Toronto , Toronto , Canada.,d Department of Molecular Genetics , University of Toronto , Toronto , Canada
| |
Collapse
|